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The  present  work  investigated  repeated  dose  and  reproductive  toxicity  of Calebin  A in
Wistar  rats.  A  study  for assessing  the mutagenic  potential  of  Calebin  A through  an  AMES
test is also  described.  Calebin  A  was  orally  administered  to  groups  of  10  male  and/or  10
female  Wistar  rats  each,  assigned  to three  dose  levels  (20,  50 and  100  mg/kg/body  weight)
once daily for  90 consecutive  days.  None  of the animals  in  any  of  the  treatment/control
groups  exhibited  any  abnormal  clinical  signs/behavioral  changes,  reproductive  as  well  as
developmental  parameters,  or gross  and  microscopic  changes  in both  male  and  female  rats.
Calebin  A was  also  evaluated  for its ability  to induce  reverse  mutations  at selected  loci  of
Salmonella  typhimurium  in the presence  and  absence  of  Aroclor  1254  induced  rat liver S9Toxicological
Histo-pathological
NOAEL
cell lines.  In conclusion,  100  mg/kg/d  of  Calebin  A  is  not  likely  to produce  any  signiﬁcant
toxic  effects in male  and female  Wistar  rats  and  no  reproductive  or developmental  toxicity
was observed  at  the  same dose  and  hence  Calebin  A  at 100  mg/kg  was  determined  as “No
Observed  Adverse  Effect  Level  (NOAEL)”  under  the  test  conditions.
©  2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is  an  open  access  article  under
Y-NC-Nthe  CC  B
1. Introduction
The genus Curcuma is a well-known spice of India. More
than 130 species and subspecies of it are found across the
world. Curcuma caesia popularly called as black turmeric,
is an erect rhizomatous perennial herb native to North-
East and Central India. Its aromatic fresh rhizomes are
applied for sprains and bruises [1]. In the Asian countries,
turmeric powder derived from the rhizomes of Curcuma
longa and C. caesia (both belong to Zingiberaceae family),
served as a culinary aid as well as an ayurvedic medicine
∗ Corresponding author. Tel.: +91 80 2839 7973; fax: +91 80 2837 3035.
E-mail address: suresh@clinworld.org (S.K. Karri).
http://dx.doi.org/10.1016/j.toxrep.2015.03.009
2214-7500/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open ac
licenses/by-nc-nd/4.0/).D  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
of extreme versatility for several thousand years. Due to
lack of any noticeable toxicity, extensive research has been
done on the useful medicinal properties of the Curcuma
constituents [2,3].
Calebin A is one of the minor components that co-occur
along with the fabled curcuminoids in C. longa. It was ﬁrst
isolated and identiﬁed by Kim [4] from C. longa and it
resembles curcuminoids closely in structure yet percep-
tibly different (Fig. 1). Calebin A, being a ferulate ester,
lacks the characteristic feature of curcuminoids i.e., 1,3-
diketonic structure. It was detected in quantities in other
Curcuma species also, especially in C. caesia (Unpublished
data).
In addition to Calebin A, isomeric Calebenoids have also
been isolated and identiﬁed from C. longa [5]. Calebin A was
cess article under the CC BY-NC-ND license (http://creativecommons.org/
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Fig. 1. Structural compar
ound to be a more powerful protector of PC-12 and other
usceptible cells from the -amyloid insult [6] than their
tructural cousins namely curcuminoids. Calebin A might
e an effective compound for the treatment of human gas-
ric and other multi-drug resistant cancer cells [7]. Calebin
 at 25 mol/L was also shown to inhibit the growth of
uman hepatoma cell line HepG2 cells than curcumin in a
ose and time dependent manner [8].
Paucity of Calebin A occurrence in Curcuma precluded
he possibility of use of naturally occurring Calebin A in a
ure form for toxicity studies. Hence an efﬁcient method
f synthesis of Calebin A was devised. The synthetic mate-
ial matched in every respect the natural material in all the
hysical and spectral properties. Production wise, brieﬂy,
7 L of isopropyl alcohol was added into 250 L stainless
teel (SS) reactor. Intermediate −1, i.e., feruloylmethane
f 3 kg was stirred with cupric oxide 1.6 kg together for
0 min. Water of 90 L was added to the above reaction
ixture, stirred for 30 min, ﬁltered and weighed. The ﬁl-
ered solid was dissolved in 33 L of ethyl acetate and stirred
or 15 min. Potassium carbonate (3.24 kg) was mixed with
ater (48 L) and stirred in 250 L SS reactor. Calebin A,
ntermediate 2 – ferulic acid (9.12 kg) was added to the
bove with stirring. Once the solution becomes homoge-
ous, tetrabutylammonium bromide (900 g) was added to
his solution. The reaction mixture was ﬁltered to get crys-
allized Calebin A. This was dried at 80 ◦C in vacuum tray
rier, milled, sieved and packed. The yield of Calebin A
as 1.3 kg. The sample of Calebin A that was used in this
tudy was pale yellow powder in color with a molecular
ormula C21H20O7 and with a correct molecular weight as
btained from mass spectra. This powder had melting point
f 138–140 ◦C, with satisfactory proton and carbon NMR
nd mass spectra, in total agreement with literature data
4]. The HPLC purity of the sample was 97.6%. The heavy
etal contents were <10 ppm and the residual solvent con-
ent was conforming to USP speciﬁcations. No microbial
ontamination was observed. In spite of the useful phar-
acological and health-promoting properties of Calebin A,
here is very little information on its toxicity data. In contin-
ation of our previous oral acute and repeated dose 28 dayCurcumin and Calebin A.
toxicity studies on Wistar rats (Majeed et al., Unpublished
results), the current study targeted 90 day oral toxicity as
well as a reproductive/developmental toxicity that could be
considered as an extension of toxicity studies on Calebin A.
2. Materials and methods
2.1. Chemicals
For reverse mutation assay, methyl methane
sulphonate (MMS), sodium azide, Nitroﬂuorene and
2-aminoanthracene were purchased from Sigma Chemical
Co. (St. Louis, MO,  USA). 9-Amino Acridine was purchased
from Fluka – Sigma Aldrich (St. Louis, MO,  USA). The
Salmonella typhimurium strains TA98, TA100, TA1535 and
TA1537 strain WP2uvrA were purchased from Molecular
Toxicology Inc. (Boone, NC, USA). A rat liver S9 fraction
induced by aroclor in male Sprague–Dawley rats was
purchased from Molecular Toxicology Inc. (Boone, NC,
USA). The chemicals and solvents used throughout the
experiments were of analytical grade.
2.2. Animals
For repeated dose and reproductive toxicity studies,
rats were housed in an environment controlled room at
22 ± 3 ◦C and relative humidity of 30–70% with the pho-
toperiod of 12 h light and 12 h darkness. Five rats of each
sex per cage were housed in sterilized standard polycarbo-
nate cages with steam sterilized clean paddy husk changed
along with the cage twice a week. Pelleted rat diet man-
ufactured by M/s  Provimi Animal Nutrition India Pvt. Ltd.,
Bangalore with ﬁxed amount of 25 g pellet diet was given
to each animal daily and water given ad libitum.
2.3. EthicsBoth repeated dose (90 days) toxicity and reproduc-
tive and developmental toxicity studies were performed in
accordance with the recommendation of the Committee for
the Purpose of Control and Supervision of Experiments on
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Table 1
Grouping for repeated dose (90 day) oral toxicity study.
Treatment groups Number of
rats/group
Sex (n)
Main groups
Vehicle control (corn oil) 20 M (10) F (10)
Low dose 20 M (10) F (10)
Mid  dose 20 M (10) F (10)
High dose 20 M (10) F (10)
Recovery groups
Vehicle control (corn oil) 10 M (5) F (5)
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M,  male; F, female; n, number.
Animals (CPCSEA) guidelines for laboratory animal facility
published in the gazette of India, December 15th 1998.
2.4. Test item preparation for dosing and procedure
In this study, the test item Calebin A was administered
orally after suspending it in corn oil at daily doses of 20,
50 and 100 mg/kg/body weight, the doses that were in
line with our earlier repeated dose (28 day) toxicity data
with 100 mg/kg/d body weight had reported ‘No Observed
Adverse Effect Level’ (NOAEL).
2.4.1. Repeated 90 day oral toxicity study [9]
The dose formulations and vehicle was administered at
the dose volume of 10 mL/kg body weight of animals, in
Main and Recovery Group animals (Table 1). Homogene-
ity of the test item in the corn oil vehicle was maintained
during dose administration by constant stirring using a
magnetic stirrer. Dose formulations or vehicle was admin-
istered by oral gavage to the respective groups once daily
at approximately the same time each day (varying by ±2 h)
for a period of 90 days. There was no administration of
test item formulation/vehicle during the 30-day recovery
period. All treated and control rats were observed once
daily for a total of 90 days in the main treatment groups. The
body weights, food consumption of all rats were recorded
on test day 1 (immediately prior to oral application) and
then on weekly basis for 90 days in main treatment groups
(immediately prior to the sacriﬁce for necropsy). Observa-
tions for neuro-behavioral toxicity symptoms e.g., visual
(response to external light source), auditory (response to
external noise source), motor (gait, ataxia) and proprio-
ceptive (righting reﬂex, threat perception) were made after
the last dose and prior to the sacriﬁce for necropsy in main
treatment groups of rats.
Blood samples were collected at the end of the treat-
ment period from main groups. All rats were fasted
overnight (water allowed) before blood collection. Blood
was collected into K2 EDTA tubes for hematology and tubes
without anticoagulant for clinical chemistry. Hematologi-
cal parameters were determined using Sysmex XT 1800iv
hematology analyzer and serum was separated in a refrig-
erated centrifuge at approximately 5000 rpm for 10 min
and analyzed using Rx Daytona (Randox) automatic ana-
lyzer for the biochemistry parameters. Rats from all groups
in the study were subjected to detailed necropsy and ﬁnd-
ings were recorded, the animals were examined visually Ta
b
le
 
2
Ef
fe
ct
 
of
 
90
 
D
os
e 
gr
ou
C
on
tr
ol
 
Tr
ea
te
d
 
(2
Tr
ea
te
d
 
(5
Tr
ea
te
d
 
(1
V
al
u
es
 
ar
e 
m
St
at
is
ti
ca
l s
i
logy Rep
f
c
a
i
2
i
5
c
i
1
e
w
i
(
m
d
o
a
r
k
a
i
s
i
o
b
w
a
w
t
P
w
a
s
w
e
p
o
s
d
m
w
(
s
h
s
e
2
s
T
v
t
a
a
p
pM. Majeed et al. / Toxico
or external abnormalities including palpable masses. On
ompletion of the gross pathology examination the tissues
nd organs were collected from all animals and preserved
n 10% formal saline.
.4.2. Reproductive/developmental toxicity
The dose formulations of Calebin A were prepared once
n 10 days during dosing period [10]. 1000, 2500 and
000 mg  of the test item was suspended after mixing in
orn oil to get formulations of 2, 5 and 10 mg/mL, admin-
stered by oral gavage once daily at the dose volume of
0 mL/kg body weight, approximately the same time on
ach day (varying by ±2 h) for the period of 2 weeks
hile pre-mating, 2 weeks at the time while mating and
n females for gestation and post-partum period. Group 1
G1) rats received vehicle control while G2, G3 and G4 ani-
als received low (20 mg/kg/d), mid  (50 mg/kg/d) and high
oses (100 mg/kg/d) respectively (Table 8). Homogeneity
f the Calebin A in the vehicle was maintained during dose
dministration by constant stirring using a magnetic stir-
er. One male to one female, 1:1 matings were allowed by
eeping them in single cages in this study.
Clinical examination was done prior to the test item
dministration on day 1 and daily thereafter (±1 day) dur-
ng treatment period. Rats were observed for changes in
kin and fur, eyes, mucous membrane occurrence of secret-
ons and excretions, changes in gait, posture and presence
f any abnormal behavior. All rats were observed for mor-
idity and mortality once daily. Males and females were
eighed on the ﬁrst day of dosing, atleast weekly there-
fter, and at termination. During pregnancy, females were
eighed on days 0, 7, 14 and 20 and within 24 h of par-
urition (day 0 or 1 post-partum) and day 4 post-partum.
ups were weighed on day 0 and day 4. Food consumption
as measured during in-life phase (pre-mating, pregnancy
nd lactation) of the experiment. Necropsy: the rats to be
acriﬁced at term, were anaesthetized with chloroform,
eighed and exsanguinated. At necropsy, the animals were
xamined visually for external abnormalities including pal-
able masses. Special attention was paid to the organs
f the reproductive system. The numbers of implantation
ites were recorded. The counting of corpora lutea was
one. The organs removed, examined and placed in 10% for-
al  saline/Bouin’s ﬁxative. Histopathological examination
as carried out on the preserved organs of vehicle control
G1) and high dose (G4) group rats. Since no organ/tissue
howed test item related histopathological changes in the
igh dose groups as compared to the control animal tis-
ues from the lower dose groups (G2 and G3) were not
xamined.
.4.3. Bacterial reverse mutation assay
The experiments were carried out using the tester
trains, plated in duplicates at each concentration [11].
he positive control factors were dissolved in DMSO
ehicle and stored at −20 ◦C; these positive control fac-
ors were methyl methane sulphonate (MMS), sodium
zide, 9-aminoacridine (9-AA), Nitroﬂuorene and 2-
minoanthracene (2-AA). A dose range-ﬁnding test was
erformed to determine the highest concentration for the
resent study, which was  performed with the ﬁve testerorts 2 (2015) 580–589 583
strains at concentrations of 312.5, 625, 1250, 2500, and
5000 g/plate, with and without the S9 mixture. The num-
ber of revertant colonies did not increase to more than
twice the value observed in the controls for any of the
tester stains. However, there were increased numbers of
revertant colonies of TA1535 with the S9 mixture. Based
on these results, a dose of 5000 g/plate was selected as
the maximum dose. Aroclor 1254 induced rat liver S9 was
used as the metabolic activation system. The S9 mix  was
prepared immediately before its use and contained 10%
S9, 1 M glucose-6-phosphate, 0.1 M nicotinamide-adenine
dinucleotide phosphate, 0.4 M MgCl2 and 1.65 M KCl in a
0.2 M phosphate buffer at pH 7.4. 100 l of tester strain,
50 l of test article and 0.5 mL  S9 mix  were added to
2.0 mL  molten selective top agar at 45 ± 2 ◦C. After mixing
thoroughly, the mixture was  overlaid onto the surface of
minimal bottom agar. When plating the vehicle and pos-
itive controls, the test article aliquot was  replaced by a
50 l aliquot of vehicle used and appropriate positive con-
trol respectively. After the overlay had solidiﬁed, the plates
were inverted and incubated for approximately 48–72 h at
37 ± 2 ◦C. Plates that were not counted immediately follow-
ing the incubation period were stored at 2–8 ◦C until colony
counting was conducted. The condition of the bacterial
background lawn was evaluated for evidence of test article
toxicity by using a colony counter. Revertant colonies for a
given tester strain and activation condition were counted
by colony counter unless the assay exhibits toxicity in the
preliminary toxicity assay [11].
The study was  conducted with and without metabolic
activation (S9 fraction) prepared from Aroclor 1254
induced rat liver as per OECD Guidelines, Section 4,
Test # 471, December, 1997. The solvent control and
appropriate positive controls (methyl methane sulphonate,
sodium azide, Nitroﬂourene, 9-aminoacridine employed
for without metabolic activation and 9-Aminoanthracene
employed for with metabolic activation) were tested
simultaneously. Selection of dose levels for the muta-
genecity assay was  based upon the toxicity and precipi-
tation proﬁle of the test article.
The preliminary assay was  conducted by exposing TA98,
TA100, TA102, TA1535 and TA1537 to vehicle controls and
to at least 7 concentrations of test article, one plate per
dose, in both the presence and absence of S9 mix. Doses
were selected such that precipitate does not interfere with
manual scoring. A dose that caused >50% reduction in the
mean number of revertants per plate relative to that of
vehicle control or a reduction in the background lawn was
considered as toxic. Hundred micorliters of tester strain
and 50 l of vehicle/test compound/positive control was
added to 2.0 mL  of molten top agar at 45 ± 2 ◦C. The mix-
ture was mixed well and overlaid onto the surface of 25 mL
of minimal bottom agar. Later, the plates were inverted
and incubated for 48–72 h at 37 ± 2 ◦C. Plates that were not
counted immediately following the incubation period were
stored at 2–8 ◦C. On the day of its use, minimal top agar
0.6% agar (w/v) and 0.5% NaCl (w/v), was melted and sup-
plemented with l-histidine and d-biotin solution to a ﬁnal
concentration of 0.5 mM each. Top agar without S9 was
supplemented with 0.5 mL of water for each 2 mL  of mini-
mal  top agar. For the preparation of media and reagents, all
584 M. Majeed et al. / Toxicology Reports 2 (2015) 580–589
Table 3
Effect of 90 days oral exposure to Calebin A on neurobehavioral response index of individual male and female wistar rats.
Dose groups No of rats Neurobehavioural response
Visual response Auditory response Motor response Proprioceptive response
Control 10 NED NED NED NED
Treated (20 mg/kg/d) 10 NED NED NED NED
NED 
NED Treated (50 mg/kg/d) 10 NED 
Treated (100 mg/kg/d) 10 NED 
NAD, no abnormality detected.
references to water imply sterile deionized water produced
by the Milli-Q reagent Water system. Bottom agar plate was
approximately 25 mL  of Minimal glucose agar containing
50 X Vogel-Bonner minimal medium E (Vogel and Bonner,
1956) solution and 40% Glucose solution containing 1.5%
(w/v) agar.
2.5. Statistical analysis
The data have been subjected to statistical evaluation
for the signiﬁcance of any test item induced changes and
their interpretation of potential for toxicity. The statisti-
cal analysis of the experimental data was carried out by
the Fishers Student’s t-test. Statistical comparisons were
evaluated at the 5% (P ≤ 0.05) signiﬁcant level. For repro-
ductive/developmental toxicity studies, all quantitative
variables like laboratory investigations (pups size and pups
survival ratio) were subjected to one-way ANOVA test.
In the case of recovery groups also, data was analyzed
using the methods stated above. Comparison of means
between treatment groups was performed. Student’s t-test
was employed for bacterial reverse mutation assay results.
3. Results and discussionIn the 90 day toxicity study, all the rats appeared
healthy and gained weight throughout the observation
period. The body weight gain of experimental and control
animals did not show any statistically signiﬁcant variation.
Table 4
Effect of 90 days oral exposure to Calebin A on mean absolute organ weight (gm)
Organ Sex Control Tre
(20
Liver Male 13.95 ± 0.37 15
Female 8.27 ± 0.44 8
Brain  Male 1.82 ± 0.04 1
Female 1.76 ± 0.03 1
Kidney Male 2.61 ± 0.07 3
Female 1.67 ± 0.07 1
Spleen Male 1.30 ± 0.34 1
Female 0.87 ± 0.04 0
Heart Male 1.27 ± 0.02 1
Female 0.99 ± 0.06 0
Adrenal Male 0.065 ± 0.001 0.0
Female 0.091 ± 0.003 0.0
Testes Male 3.46 ± 0.07 3
Uterus Female 0.538 ± 0.04 0.6
Epididymis Male 1.51 ± 0.03 1
Ovary Female 0.079 ± 0.002 0.0
Values are mean ± SE of 10 animals.
Statistical signiﬁcance was  set at P < 0.05.NED NED
NED NED
No statistically signiﬁcant changes in food consumption
were observed from week 0 to 13 in both male and female
animals across control and treated groups (Table 2). There
were no indications of any test-substance related neu-
robehavioral toxicity symptoms e.g., visual (response to
external light source), auditory (response to external noise
source), motor (gait, ataxia) and proprioceptive (righting
reﬂex, threat perception), made after the last dose and
prior to the sacriﬁce for necropsy between control and
treatment receiving group animals (Table 3). The mean
absolute organ weight of male and female rats at necropsy
observed for liver, brain, kidney, spleen, heart, adrenal,
testes, uterus, epididymis and ovary between control
and treatment groups was not statistically signiﬁcant
(Table 4), and no abnormalities detected. Hematology
(Table 5) and biochemistry (Table 6) proﬁles suggest
that all the parameters therein were normal and the
treatment group values were same as that of the control
group values, with no statistically signiﬁcant difference.
Sporadic variations like decreased differential leukocyte
counts (only lymphocytes) and increased PLT to male and
female rats exposed to test item did not correlate with
dose, sex or other physiologically signiﬁcant parameters
to be considered exposure related effect. The activities of
serum enzymes like GOT and GPT, and other important
biochemical constituents like glucose, creatinine, urea,
total protein, triglyceride, albumin, uric acid, cholesterol
and globulin, that are indicative of metabolic and patho-
logical abnormalities, showed no signiﬁcant change in
 of male and female wistar rats at necropsy.
ated
 mg/kg/d) (50 mg/kg/d) (100 mg/kg/d)
.52 ± 0.85 14.39 ± 0.68 13.55 ± 0.83
.31 ± 0.38 8.99 ± 0.32 8.36 ± 0.26
.77 ± 0.08 1.78 ± 0.06 1.86 ± 0.06
.74 ± 0.03 1.82 ± 0.04 1.67 ± 0.06
.02 ± 0.14 2.76 ± 0.03 2.77 ± 0.07
.60 ± 0.03 1.65 ± 0.05 1.59 ± 0.04
.05 ± 0.08 1.10 ± 0.04 1.04 ± 0.09
.78 ± 0.04 0.91 ± 0.05 0.84 ± 0.04
.33 ± 0.06 1.30 ± 0.04 1.37 ± 0.14
.88 ± 0.04 0.89 ± 0.03 0.94 ± 0.05
63 ± 0.003 0.059 ± 0.001 0.064 ± 0.002
86 ± 0.002 0.081 ± 0.007 0.084 ± 0.001
.41 ± 0.12 2.99 ± 0.17 3.43 ± 0.08
72 ± 0.005 0.670 ± 0.100 0.569 ± 0.042
.67 ± 0.05 1.52 ± 0.07 1.55 ± 0.04
81 ± 0.008 0.131 ± 0.030 0.120 ± 0.003
M. Majeed et al. / Toxicology Reports 2 (2015) 580–589 585
Table  5
Effect of 90 days oral exposure to Calebin A on mean hematology data of male and female wistar rats at necropsy.
Parameter Sex Control Treated
20 mg/kg/d 50 mg/kg/d 100 mg/kg/d
WBC  (103/l) Male 12.66 ± 1.34 10.52 ± 1.43 11.95 ± 2.16 9.38 ± 1.53
Female 5.80 ± 0.78 5.42 ± 0.70 4.75 ± 1.48 5.29 ± 0.62
RBC  (106/l) Male 8.74 ± 0.14 8.82 ± 0.14 8.46 ± 0.13 8.76 ± 0.15
Female 7.67 ± 0.11 8.04 ± 0.13 7.96 ± 2.65 7.95 ± 0.13
HGB  (g/dl) Male 14.17 ± 0.16 14.29 ± 0.21 13.88 ± 0.21 14.56 ± 0.29
Female 12.14 ± 1.23 13.64 ± 0.13 13.82 ± 0.13 13.72 ± 0.19
HCT  (%) Male 42.26 ± 0.49 42.66 ± 0.68 41.77 ± 0.63 42.99 ± 0.87
Female 38.94 ± 0.47 40.37 ± 0.41 40.87 ± 0.33 40.30 ± 0.59
MCV  (ﬂ) Male 48.39 ± 0.39 48.10 ± 0.78 49.38 ± 0.58 49.07 ± 0.35
Female 50.94 ± 0.56 50.23 ± 0.72 51.47 ± 0.57 50.54 ± 0.34
MCH  (pg) Male 16.21 ± 0.14 16.22 ± 0.26 14.89 ± 1.50 16.62 ± 0.13
Female 17.39 ± 0.16 16.96 ± 0.22 17.30 ± 0.20 17.27 ± 0.15
MCHC  (g/dl) Male 33.54 ± 0.15 33.67 ± 0.14 33.24 ± 0.16 33.92 ± 0.13
Female 34.16 ± 0.12 33.81 ± 0.15 33.70 ± 0.22 34.05 ± 0.13
PLT  (103/l) Male 803.00 ± 31.36 906.50 ± 32.91 881.63 ± 27.55 882.60 ± 40.92
Female
NEUT  (%) Male 14.73 ± 1.95 21.52 ± 1.86 19.23 ± 1.54 21.64 ± 2.94
Female
LYMPH (%) Male 80.41 ± 1.98 71.78 ± 1.95 74.14 ± 1.70 69.60 ± 2.33
Female
MONO (%) Male 3.08 ± 0.23 3.83 ± 0.44 3.86 ± 0.51 3.29 ± 0.24
Female
EO  (%) Male 1.68 ± 0.23 2.45 ± 0.37 2.70 ± 0.45 3.02 ± 0.80
Female
BASO  (%) Male 0.10 ± 0.02 0.14 ± 0.05 0.07 ± 0.01 0.41 ± 0.02
V
S
e
H
d
a
o
T
E
VFemale
alues are mean ± SE of 10 animals each.
tatistical signiﬁcance was set at P < 0.05.
xperimental animals as compared to control animals.
owever, stray variations like GOT activity showing mild
ecrease in female rats of 50 and 100 mg/kg/d dose group
nd decrease level of cholesterol in rats of 50 mg/kg/d were
bserved. These changes, in absence of any physiological
able 6
ffect of 90 days oral exposure to Calebin A on Mean serum biochemical data of m
Parameter Sex Control T
2
Glucose (mg/dl) Male 79.93 ± 9.00 
Female 93.21 ± 5.17 
Creatinine (mg/dl) Male 0.50 ± 0.06 
Female 0.56 ± 0.03 
GOT  (U/L) Male 94.50 ± 9.91 
Female 128.20 ± 14.61 
Urea  (mg/dl) Male 32.69 ± 2.57 
Female 32.84 ± 2.18 
Total  protein (gm/dl) Male 6.36 ± 0.39 
Female 6.72 ± 0.28 
TG  (mg/dl) Male 191.46 ± 8.96 
Female 203.92 ± 20.01 
Albumin (gm/dl) Male 3.27 ± 0.17 
Female 3.35 ± 0.13 
Uric  acid (mg/dl) Male 0.89 ± 0.13 
Female 0.96 ± 0.12 
Cholesterol (mg/dl) Male 54.01 ± 6.18 
Female 56.21 ± 3.60 
Globulin (mg/dl) Male 3.08 ± 0.24 
Female 3.36 ± 0.17 
GPT  (U/L) Male 57.80 ± 9.60 
Female 45.00 ± 3.41 
alues are mean ± SE of 10 animals.
* Signiﬁcant at the level of P < 0.05.abnormality, appear to be spontaneous and may  not be
related to the exposure to the test item. In the individual
gross morphology and histopathology of male and female
rats (Table 7), no abnormality detected for majority of the
animals in both control and high dose receiving group
ale and female wistar rats at necropsy.
reated
0 mg/kg/d 50 mg/kg/d 100 mg/kg/d
74.16 ± 8.86 100.65 ± 9.05 86.66 ± 10.33
94.55 ± 7.03 80.14 ± 9.93 104.86 ± 7.13
0.43 ± 0.06 0.56 ± 0.07 0.44 ± 0.06
0.55 ± 0.03 0.38 ± 0.04 0.50 ± 0.05
91.90 ± 9.96 113.50 ± 12.36 93.00 ± 8.32
110.80 ± 11.65 69.44 ± 9.23* 81.60 ± 6.78*
30.08 ± 2.96 41.24 ± 3.23 40.53 ± 4.01
35.81 ± 2.66 31.82 ± 3.07 36.33 ± 2.69
6.21 ± 0.33 6.63 ± 0.29 6.39 ± 0.19
6.35 ± 0.36 6.88 ± 0.15 6.36 ± 0.19
143.16 ± 12.93 190.40 ± 14.10 159.97 ± 15.09
155.21 ± 9.16 154.45 ± 10.20 155.65 ± 10.69
3.18 ± 0.18 3.41 ± 0.12 3.39 ± 0.20
3.23 ± 0.16 3.88 ± 0.04 3.55 ± 0.09
0.96 ± 0.13 0.83 ± 0.06 0.83 ± 0.07
0.98 ± 0.13 0.65 ± 0.12 0.75 ± 0.06
40.15 ± 2.96 53.44 ± 6.07 54.53 ± 4.82
54.28 ± 4.76 41.46 ± 3.66* 47.44 ± 3.65
2.96 ± 0.25 3.21 ± 0.20 2.94 ± 0.09
3.15 ± 0.21 3.01 ± 0.12 2.71 ± 0.12
51.20 ± 5.30 55.30 ± 5.56 46.50 ± 4.99
45.31 ± 3.33 35.66 ± 3.39 41.50 ± 2.42
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Table 7
Effect of 90 days oral exposure to Calebin A on Individual gross morphology and histopathology of male and female wistar rats.
Dose group Sex Animal number Mode of
deatha
Period of
study
Necropsy
observation
Histopathological observation
Control Male 1 TS 90 Days NED Spleen: mild lymphoid hyperplasia
Female 1 TS 90 Days NED NED
Male 2 TS 90 Days NED NED
Female 2 TS 90 Days NED NED
Male 3 TS 90 Days NED NED
Female 3 TS 90 Days NED NED
Male 4 TS 90 Days NED Lung: mild alveolar consolidation
Female 4 TS 90 Days NED NED
Male 5 TS 90 Days NED NED
Female 5 TS 90 Days NED Ovary: mild congestion
Male 6 TS 90 Days NED Testis: mild oligospermia
Female 6 TS 90 Days NED NED
Male 7 TS 90 Days NED NED
Female 7 TS 90 Days NED Lung: mild alveolar consolidation
Male 8 TS 90 Days NED Kidney: mild focal interstitial nephritis
Female 8 TS 90 Days NED NED
Male 9 TS 90 Days NED NED
Female 9 TS 90 Days NED NED
Male 10 TS 90 Days NED NED
Female 10 TS 90 Days NED NED
Treated (100 mg/kg/d) Male 31 TS 90 Days NED NED
Female 31 TS 90 Days NED Uterus: mild hydrometra
Male 32 TS 90 Days NED NED
Female 32 TS 90 Days NED NED
Male 33 TS 90 Days NED Lung: mild inﬁltration of inﬂammatory cells
Female 33 TS 90 Days NED NED
Male 34 TS 90 Days NED NED
Female 34 TS 90 Days NED Lung: mild alveolar consolidation
Male 35 TS 90 Days NED Testis: mild oligospermia
Female 35 TS 90 Days NED NED
Male 36 TS 90 Days NED Spleen: mild lymphoid hyperplasia
Female 36 TS 90 Days NED NED
Male 37 TS 90 Days NED NED
Female 37 TS 90 Days NED NED
Male 38 TS 90 Days NED Liver: mild hepatocellular degeneration
Female 38 TS 90 Days NED Kidney: mild focal interstitial nephritis
Male  39 TS 90 Days NED NED
Female 39 TS 90 Days NED NED
90 Day
90 Day
o abnoMale 40 TS 
Female 40 TS 
a FD, found dead; MS, moribund sacriﬁce; TS, terminal sacriﬁce; NAD, n
(G4). No necropsy was observed in both the animal groups
with few commonly seen histopathological observations
between control and high dose (G4) group animals
(Table 7). The testis of one male revealed oligospermia and
the epididymis of all animals and testis of other animals
did not show any change in control group animals. Females
of control group did not reveal any lesion whereas uterus
Table 8
Grouping and dose formulation for reproductive/developmental toxicity study.
Main groups
Group no. Treatment groups Dose (mg/kg/d) 
G1 Vehicle control 0 
G2  Low dose 20 
G3  Mid  dose 50 
G4  High dose 100 
M,  male; F, female.s NED NED
s NED NED
rmality detected.
of one female showed hydrometra. In the high dose group
(G4), one male showed oligospermia in testis, ovary of
one female rat revealed congestion. Lesions observed in
control and high dose group animals were comparable
to each other and also they appear to be incidental and
spontaneous in nature and cannot be related to the test sub-
stance, Calebin A. There were no signiﬁcant observations
Concentration (mg/m) No. of rats Sex
NA 10 M
10 F
2 10 M
10 F
5 10 M
10 F
10 10 M
10 F
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Table  9
Organ weights (g) of animals in reproductive/developmental toxicity
study.
Group Male Female
Testes Epididymis Ovaries Uterus
Control 3.09 1.22 0.34 0.93
f
t
t
g
c
o
t
A
e
o
w
Table 10
Body weight of male and female pups (g) in reproductive/developmental
toxicity study.
Group Day 0 Day 4
Male Female Male Female
Control 5.63 5.62 10.15 9.90
T
C
T
R
N20 mg/kg 3.32 1.22 0.40 0.90
50 mg/kg 2.97 1.10 0.38 0.93
100 mg/kg 3.02 1.20 0.36 0.86
ound in the recovery group (30 days) of animals in any of
he parameters studied and hence not tabulated.
In the reproductive and developmental toxicity study,
he organ weight differences between control and treated
roup male rats for testes and epididymis are not statisti-
ally signiﬁcant. Similarly in female rats, no gross changes
bserved in the weights of ovaries and uterus between con-
rol and other treatment receiving group animals (Table 9).
ll animals in all groups pups, both control and treated
xhibited a comparable body weight gain during the course
f the study (day 0 and day 4). There was no loss in body
eight or difference in body weight gain between groups
able 11
orpora lutea (Cl) and implantation sites (Imp) in numbers in reproductive/devel
Group Corpora lutea in average number Implantation sites
Left Right Total
Control 5.70 5.80 11.50 8.40 
20  mg/kg 5.50 5.70 11.20 8.30 
50  mg/kg 6.10 6.30 12.40 9.10 
100  mg/kg 6.50 6.30 12.90 9.60 
able 12
eports of effects on reproduction/development.
Observation Values
Dosage (units) Control
0 mg/kg
Pairs started (N) 10 
Females showing evidence of copulation (N) 10 
Females achieving pregnancy (N) 9 
Conceiving days 1–5 (N) 6 
Conceiving days 6–(N) 3 
Pregnancy ≤ 21 days (N) 3 
Pregnancy = 22 days (N) 5 
Pregnancy ≥ 23 days (N) 1 
Dams  with live young born (N) 9 
Dams  with live young at day 4 pp (N) 9 
Corpora lutea/dam (mean) 11.50 
Implants/dam (mean) 8.40 
Live  pups/dam at birth (mean) 8.33 
Live  pups/dam at day 4 (mean) 8.11 
Sex  ratio (m/f) at birth (mean) 1.08 
Sex  ratio (m/f) at day 4 (mean) 1.11 
Pup  weight at birth (mean) 5.62 
Pup  weight at day 4 (mean) 10.03
Abnormal pups
Dams with 0 0 
Dams  with 1 0 
Dams  with ≥2 0 
Loss  of offspring
Pre-implantation (corpora lutea minus implantations) 3.10 
Pre-natal/post–implantations (implantations minus live births) 0.27 
Post-natal (live births minus alive at post-natal day 4) 0.22 
, number; PP, post partum.20 mg/kg 5.73 5.82 10.68 10.25
50 mg/kg 5.54 5.40 10.39 10.10
100 mg/kg 5.55 5.66 10.29 9.91
during the course of the study (Table 10). There were no sig-
niﬁcant changes observed in the average number of corpora
lutea and percent of successful implantation between con-
trol and treatment group animals (Table 11). All group of
animals showed no difference in achieving pregnancy, with
majority of them conceiving in 1–5 days. All group female
rats showed the preliminary signs of pregnancy in less than
or equal to 22 days. No signiﬁcant difference in mean values
of implants between control and other treatment groups.
The mean pups weight at day 4 was  comparable between
control and high dose receiving group animals (G4). No
changes observed in pre-implantation, post natal and post
opmental toxicity study.
 in average number (IMP) Percent of successful implantation %
73.11
73.48
73.47
73.67
/d
Low
20 mg/kg/d
Medium
50 mg/kg/d
High
100 mg/kg/d
10 10 10
10 10 10
9 9 10
7 8 8
2 1 2
2 2 3
6 5 6
1 2 1
9 9 10
9 9 10
11.20 12.40 12.90
8.50 9.10 9.60
8.35 8.95 9.00
8.33 9.56 9.00
1.2 1.12 1.25
1.14 1.12 1.25
5.77 5.47 5.61
10.46 10.25 10.10
0 0 0
0 0 0
0 0 0
2.90 3.30 3.30
0.26 0.57 0.60
0.22 0.11 0.00
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Table 13
Effect of Calebin A on bacterial reverse mutation assay with (+S9) mix  (Ames).
Concentration (g/plate) Bacterial strains
TA 98 TA 100 TA 102 TA 1535 TA 1537
Mean revertants/plate ± SEM
Vehicle 40 ± 3.5 191 ± 4 351 ± 1.5 15 ± 0.5 14 ± 0.5
312.5  43 ± 3 187 ± 2 330 ± 1 16 ± 2 11 ± 0.5
625  41 ± 2.5 179 ± 3.5 303 ± 4.5 19 ± 1.5 11 ± 1
1250  41 ± 4 182 ± 2.5 319 ± 1.5 17 ± 3 16 ± 1
2500  42 ± 2.5 188 ± 0.5 303 ± 4.5 11 ± 1 14 ± 2
5000  40 ± 1.5 197 ± 2.5 328 ± 2.5 14 ± 1.5 15 ± 2.5
Positive control 1050a ± 37.5 1226a ± 28.5 2394a ± 12.5 335a ± 16.5 203a ± 18.5
a Aminoanthracene (2 g/plate).
Data are presented as mean ± standard deviation.
Table 14
Effect of Calebin A on bacterial reverse mutation assay without (+S 9) mix.
Concentration (g/plate) Bacterial strains
TA 98 TA 100 TA 102 TA 1535 TA 1537
Mean revertants/plate ± SEM
Vehicle 21 ± 1 111 ± 2 201 ± 3.5 10 ± 1 11 ± 1
312.5  21 ± 0 122 ± 2 203 ± 1.5 8 ± 1 9 ± 1
625  19 ± 2.5 119 ± 2.5 211 ± 0.5 9 ± 0 10 ± 1.5
1250  24 ± 2.5 112 ± 2.5 198 ± 3.5 11 ± 0.5 11 ± 1.5
2500  22 ± 2 105 ± 3.5 198 ± 0.5 12 ± 0.5 11 ± 2
5000  18 ± 3 115 ± 2 202 ± 3 9 ± 0.5 10 ± 1
Positive control 701a ± 8.5 723b ± 21 1654c ± 12.5 407d ± 8 123e ± 11
Data are presented as mean ± standard deviation.
a Nitroﬂuorene (3 g/plate).
b Methyl methane sulphonate (1.5 l/plate).
c Methyl methane sulphonate (2 l/plate).
d Sodium azide (2 g/plate).
e 9-Aminoacridine (85 g/plate).
natal loss of off-spring between all the groups of animals
(Table 12).
The Ames test uses amino acid-requiring strains of S.
typhimurium and E. coli to detect point mutations involving
substitution, addition, or deletions of one or more DNA
base pairs [12] The bacterial reverse mutation (Ames) test
is a biological assay that is used to evaluate the mutagenic
activity of medical compounds. For the initial screening, the
Ames test is used worldwide to determine the mutagenic
activity of new medicines as many carcinogenic materials
were shown to have a high predictive value in rodents
when a positive result is obtained [13,14]. Mutagenecity
testing using the Ames test is one of the most frequently
used method and is recommended by regulatory agencies
for determining genetic risk (Korea Food and Drug Admin-
istration, U.S. Food and Drug Administration, Organization
for Economic Cooperation and Development). The exper-
imental methods used in the study were based on the
published reports by Maron and Ames with minor modiﬁ-
cations. S. typhimurium tester strains TA 98 and TA1537 (to
detect frame-shift mutagens), TA100 and TA1535 (to detect
base pair-substitution mutagens) and TA102 for oxidative
mutagens were obtained from Molecular Toxicology Inc.
(Boone, USA) and were used as the tester strains. No
positive mutagenic response was observed in any of the S.
typhimurium tested compared with the concurrent vehicle
control groups regardless of the presence or absence of
the S9 mixture. The positive controls showed signiﬁcantlyincreased numbers of revertant colonies, indicating that
the assay was valid. In the results of the mutagenecity
assay, the concentrations of Calebin A selected for the
study ranged from 312.5 to 5000 g/plate. Calebin A gave
a negative response in the presence (Table 13) and absence
(Table 14) of rat liver S9 in the assay up to 5000 g/plate.
4. Conclusion
Calebin A, in the repeated dose 90 day oral toxic-
ity study and in the reproductive/developmental toxicity
study, showed no signs of toxicity and hence it could
be concluded that a repeated oral exposure to test item
Calebin A, up to 100 mg/kg/d does not produce any toxic
effects and may  be treated as ‘No Observed Adverse Effect
Level’ (NOAEL) under the test conditions employed. Also, as
Calebin A exhibited a negative response in the presence and
absence of Aroclor 1254 induced rat liver S9 in the assay up
to 5000 g/plate, it was concluded that Calebin A was not
mutagenic in the Bacterial Reverse Mutation Assay.
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